Mesenchymal Stem Cells Promote Pancreatic Tumor Growth by Inducing Alternative Polarization of Macrophages
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Pancreatic cancer is characterized by an extensive desmoplastic stroma, the functional relevance of which is poorly understood. Activated fibroblasts are a prevalent component of the stroma, and traditionally, these cells have been considered as a homogenous population derived from pancreatic stellate cells. In this study, we highlight a previously unappreciated heterogeneity of the fibroblast population within the stroma. In particular, a subset of stromal fibroblasts has characteristics of mesenchymal stem cells (MSCs). MSCs are present in the normal pancreas as well as in the carcinomatous pancreas (CA-MSCs). Here, we determine that CA-MSCs have increased tumor-promoting function compared with MSCs in normal pancreas. This ability to promote tumor growth is associated with CA-MSCs' unique ability to promote alternative macrophage polarization. Thus, our study identifies a previously uncharacterized cell population within the stroma and sheds light on tumor-promoting interactions between different components of the stroma. SIGNIFICANCE: Targeting the stroma is emerging as a new paradigm in pancreatic cancer; however, efforts to that effect are hampered by our limited understanding of the nature and function of stromal components. Here, we uncover previously unappreciated heterogeneity within the stroma and identify interactions among stromal components that promote tumor growth and could be targeted therapeutically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991 · cited 2×
“A population of mesenchymal stem cells (P-MSCs) was identified in the normal human and mouse pancreas [8,9]; however, whether MSCs are present in pancreatic carcinoma and what their function might be during carcinogenesis remained unclear.”
BackgroundMicroenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 1×
“The accumulation of a desmoplastic stroma occurs from the onset of pancreatic carcinogenesis and is evident in the precursor lesions of pancreatic cancer known as pancreatic intraepithelial neoplasia or PanINs [2].”
BackgroundMesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 1×
“In breast cancer, bone marrow–derived MSCs promote the metastasis of tumor cells through a CCL5-mediated effect [11].”
BackgroundÖzdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 1×
“MSCs Promote Macrophage Differentiation and Polarization to an Alternatively Activated Subtype Pancreatic cancer fibroblasts, including the FAP+ subset, are known to modulate the immune response, thus affecting tumor growth [32,33].”
BackgroundPancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 1×
“We use a genetically engineered mouse model of pancreatic cancer, the KC mouse (Ptf1a-Cre;LSL-Kras) [14], that expresses an oncogenic form of Kras, thus recapitulating the most common genetic alteration in human PanINs and pancreatic cancer [15,16].”
MethodSelective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 1×
“Administration of diphtheria toxin (DT) to Cd11b-DTRmice depletes all CD11b+ cells, including monocytes and macrophages [31].”
BackgroundErez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515 · cited 1×
“MSCs Promote Macrophage Differentiation and Polarization to an Alternatively Activated Subtype Pancreatic cancer fibroblasts, including the FAP+ subset, are known to modulate the immune response, thus affecting tumor growth [32,33].”
Background
Cited by
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Diversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265
The Pros and Cons of Mesenchymal Stem Cell-Based Therapies
Musiał-Wysocka, A., Kot, M., & Majka, M. (2019) · Cell Transplantation · doi:10.1177/0963689719837897 · Cited by 534
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer
Halbrook, C. J., & Lyssiotis, C. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.006 · Cited by 393
Li, W., Zhang, X., Wu, F., Zhou, Y., Bao, Z., Li, H., Zheng, P., & Zhao, S. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2131-y · Cited by 359
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neesse, A., Bauer, C. A., Öhlund, D., Lauth, M., Buchholz, M., Michl, P., Tuveson, D. A., & Gress, T. M. (2019) · Gut · doi:10.1136/gutjnl-2018-316451 · Cited by 353
Microenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment
Helms, E., Onate, M. K., & Sherman, M. H. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1353 · Cited by 283
Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer
Steele, N. G., Biffi, G., Kemp, S. B., Zhang, Y., Drouillard, D., Syu, L., Hao, Y., Oni, T. E., Brosnan, E., Elyada, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3715 · Cited by 283
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma
Garcia, P. E., Adoumie, M., Kim, E. C., Zhang, Y., Scales, M. K., El-Tawil, Y. S., Shaikh, A. Z., Wen, H.-J., Bednar, F., Allen, B. L., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.05.004 · Cited by 110
Self-citationTruong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Kras and tumor immunity: friend or foe?
Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85
“3) (Mathew et al. 2016; Waghray et al. 2016).”
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity
Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212429 · Cited by 67
“Immunosuppressive cytokines produced by M2 TAMs and MSC2 down-regulated the anti-tumor immune response, enabling immune evasion and the uncontrolled proliferation of pancreatic cancer cells [17].”
BackgroundResultInfluential
Metadata
- Authors
- Mathew, E., Brannon, A. L., Del Vecchio, A., Garcia, P. E., Penny, M. K., Kane, K. T., Vinta, A., Buckanovich, R. J., & di Magliano, M. P.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 18
- Issue
- 3
- Pages
- 142-151
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2298284797
- Cited by
- 121
- References
- 16
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.